Concepts (109)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lymphoma, T-Cell, Peripheral | 8 | 2022 | 134 | 1.390 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2020 | 169 | 0.630 |
Why?
|
DNA Helicases | 2 | 2020 | 861 | 0.590 |
Why?
|
Gene Expression Regulation, Neoplastic | 7 | 2021 | 8426 | 0.490 |
Why?
|
Lymphoma, T-Cell | 3 | 2022 | 299 | 0.400 |
Why?
|
Gene Expression Profiling | 9 | 2022 | 9438 | 0.340 |
Why?
|
Splenomegaly | 1 | 2018 | 190 | 0.310 |
Why?
|
Burkitt Lymphoma | 2 | 2022 | 328 | 0.300 |
Why?
|
Oncogene Fusion | 1 | 2017 | 99 | 0.290 |
Why?
|
Caveolin 1 | 1 | 2018 | 264 | 0.280 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2022 | 1378 | 0.260 |
Why?
|
Phenotype | 1 | 2020 | 16365 | 0.210 |
Why?
|
Ikaros Transcription Factor | 1 | 2022 | 217 | 0.190 |
Why?
|
Sequence Analysis, RNA | 1 | 2017 | 2013 | 0.170 |
Why?
|
Lymphoma, Follicular | 1 | 2022 | 435 | 0.160 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2019 | 3598 | 0.140 |
Why?
|
Splenic Neoplasms | 1 | 2017 | 100 | 0.140 |
Why?
|
Neoplasm Proteins | 1 | 2019 | 3703 | 0.140 |
Why?
|
Hematologic Neoplasms | 1 | 2018 | 1831 | 0.140 |
Why?
|
Immunoglobulins | 1 | 2019 | 881 | 0.130 |
Why?
|
Antigens, CD1d | 1 | 2016 | 220 | 0.130 |
Why?
|
Transcription, Genetic | 1 | 2019 | 7723 | 0.120 |
Why?
|
MicroRNAs | 2 | 2021 | 3747 | 0.120 |
Why?
|
Mutation | 6 | 2022 | 29784 | 0.120 |
Why?
|
Interferon-gamma | 1 | 2022 | 3203 | 0.120 |
Why?
|
Gene Silencing | 1 | 2020 | 1538 | 0.110 |
Why?
|
Oncogenes | 1 | 2019 | 1265 | 0.110 |
Why?
|
Immunologic Factors | 1 | 2022 | 1582 | 0.110 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2022 | 1860 | 0.110 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2017 | 671 | 0.110 |
Why?
|
Signal Transduction | 4 | 2019 | 23404 | 0.110 |
Why?
|
RNA Interference | 1 | 2020 | 2890 | 0.100 |
Why?
|
Lymphoma, B-Cell | 1 | 2017 | 931 | 0.090 |
Why?
|
DNA Copy Number Variations | 1 | 2019 | 1940 | 0.090 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2017 | 2948 | 0.090 |
Why?
|
Algorithms | 2 | 2019 | 13885 | 0.080 |
Why?
|
Cell Line, Tumor | 3 | 2020 | 16687 | 0.080 |
Why?
|
Promoter Regions, Genetic | 1 | 2020 | 5867 | 0.080 |
Why?
|
Biopsy | 1 | 2020 | 6757 | 0.080 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2022 | 5169 | 0.070 |
Why?
|
Databases, Nucleic Acid | 1 | 2017 | 211 | 0.070 |
Why?
|
Genome-Wide Association Study | 2 | 2021 | 12264 | 0.060 |
Why?
|
Cell Proliferation | 1 | 2020 | 10480 | 0.060 |
Why?
|
Multiple Myeloma | 1 | 2022 | 5180 | 0.060 |
Why?
|
Immunophenotyping | 2 | 2019 | 1880 | 0.060 |
Why?
|
Models, Biological | 1 | 2020 | 9582 | 0.060 |
Why?
|
Sequence Alignment | 1 | 2017 | 2256 | 0.050 |
Why?
|
Liver Neoplasms | 1 | 2017 | 4252 | 0.050 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2022 | 2540 | 0.050 |
Why?
|
Humans | 17 | 2022 | 744220 | 0.040 |
Why?
|
Methyltransferases | 1 | 2022 | 367 | 0.040 |
Why?
|
Prognosis | 4 | 2022 | 29050 | 0.040 |
Why?
|
Cell Line | 2 | 2019 | 15999 | 0.040 |
Why?
|
Genomics | 1 | 2015 | 5722 | 0.040 |
Why?
|
Immunoblastic Lymphadenopathy | 1 | 2019 | 35 | 0.040 |
Why?
|
GATA3 Transcription Factor | 1 | 2019 | 157 | 0.040 |
Why?
|
Killer Cells, Natural | 1 | 2017 | 2133 | 0.040 |
Why?
|
Ubiquitination | 1 | 2022 | 1011 | 0.040 |
Why?
|
RNA | 1 | 2017 | 2749 | 0.040 |
Why?
|
Thalidomide | 1 | 2022 | 890 | 0.040 |
Why?
|
T-Box Domain Proteins | 1 | 2019 | 471 | 0.030 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2016 | 82 | 0.030 |
Why?
|
Mice | 4 | 2022 | 81178 | 0.030 |
Why?
|
Antigens, Ly | 1 | 2016 | 291 | 0.030 |
Why?
|
Molecular Targeted Therapy | 2 | 2017 | 2727 | 0.030 |
Why?
|
Surface Plasmon Resonance | 1 | 2015 | 274 | 0.030 |
Why?
|
Computer Simulation | 1 | 2017 | 6196 | 0.030 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2015 | 906 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2021 | 6313 | 0.030 |
Why?
|
Software | 1 | 2017 | 4442 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2022 | 19907 | 0.030 |
Why?
|
Mice, Nude | 1 | 2019 | 3689 | 0.030 |
Why?
|
Male | 8 | 2019 | 350027 | 0.030 |
Why?
|
Blotting, Western | 1 | 2019 | 5180 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2019 | 3557 | 0.020 |
Why?
|
Streptococcus pneumoniae | 1 | 2016 | 714 | 0.020 |
Why?
|
Animals | 4 | 2022 | 168788 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 1692 | 0.020 |
Why?
|
Female | 7 | 2019 | 380197 | 0.020 |
Why?
|
Cell Survival | 1 | 2019 | 5881 | 0.020 |
Why?
|
Computational Biology | 1 | 2019 | 3523 | 0.020 |
Why?
|
NF-kappa B | 1 | 2015 | 2501 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2017 | 2848 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11368 | 0.020 |
Why?
|
Models, Molecular | 1 | 2015 | 5458 | 0.020 |
Why?
|
Base Sequence | 1 | 2017 | 12801 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2019 | 11007 | 0.020 |
Why?
|
Adult | 4 | 2022 | 214035 | 0.020 |
Why?
|
Disease Management | 1 | 2015 | 2458 | 0.020 |
Why?
|
Child, Preschool | 2 | 2017 | 40992 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2015 | 4419 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 2017 | 4665 | 0.010 |
Why?
|
Protein Binding | 1 | 2015 | 9392 | 0.010 |
Why?
|
Antineoplastic Agents | 2 | 2017 | 13668 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2017 | 19227 | 0.010 |
Why?
|
Aged | 3 | 2019 | 163253 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2016 | 14556 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 25043 | 0.010 |
Why?
|
Young Adult | 2 | 2017 | 56436 | 0.010 |
Why?
|
Middle Aged | 3 | 2019 | 213367 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2015 | 7908 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2017 | 9647 | 0.010 |
Why?
|
Neoplasms | 1 | 2018 | 21672 | 0.010 |
Why?
|
Child | 2 | 2017 | 77679 | 0.010 |
Why?
|
Adolescent | 2 | 2017 | 85759 | 0.010 |
Why?
|
Transcription Factors | 1 | 2017 | 12207 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 11493 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2017 | 57768 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2015 | 63119 | 0.010 |
Why?
|
Concepts
(109)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(7)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_